Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-07-12
2005-07-12
Criares, Theodore J. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S227800, C514S236800, C514S254050, C514S255050, C514S318000, C514S333000, C514S341000, C514S371000, C514S377000, C514S398000, C514S404000, C514S406000, C514S426000, C514S447000, C514S472000
Reexamination Certificate
active
06916814
ABSTRACT:
Disclosed are methods of treating certain cytokine mediated diseases or conditions using novel aromatic heterocyclic compounds of the formula(I) wherein Ar1,Ar2,L,Q and X are described herein.
REFERENCES:
patent: 6297381 (2001-10-01), Cirillo et al.
patent: 6319921 (2001-11-01), Cirillo et al.
patent: 6358945 (2002-03-01), Breitfelder et al.
patent: 2002/0061901 (2002-05-01), Robl et al.
patent: WO 97/28149 (1997-08-01), None
patent: WO 99/32110 (1999-07-01), None
patent: WO 99/32111 (1999-07-01), None
patent: WO 99/32463 (1999-07-01), None
patent: WO 01/36403 (2000-11-01), None
patent: WO 01/96311 (2001-12-01), None
patent: WO 02/34259 (2002-05-01), None
Steiner, G.; “Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study”; Lancet, vol. 357, No. 9260, 2001, pp. 905-910.
Serfaty-Lacrosniere, C. et al; “Homozygous Tangier disease and cardiovascular disease”; Atherosclerosis, vol. 107, No. 1, 1994, pp. 85-98; XP002225804.
Susekov, A. V. et al; “Lipanor treatment of atherogenic hyperlipoproteinemia”; Terapevticheskii Arkhiv; vol. 70, No. 9, 1998, pp. 57-61; XP-002225800.
Papademetriou, Vasilios et al; “Influence of risk factors on peripheral and cerebrovascular disease in men with coronary artery disease, low high-density lipoprotein cholesterol levels, and desirable low-density lipoprotein cholesterol levels”; American Heart Journal; vol. 136, No. 4 Part 1.
Kirchgaessler, K. U. et al; “Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200 mg in a drug-monitoring programme involving 9884 patients with dyslipidaemia”; Clinical Drug Investigation, vol. 15, No. 3, 1998, pp. 197-204; XP002225802.
Cimminiello, C. et al; “Fibrinolytic response in subjects with hypertriglyceridemia and low HDL cholesterol”; Biomedicine & Pharmacotherapy, vol. 51, No. 4, 1997, pp. 164-169; XP002225803.
Moss Neil
Regan John Robinson
Boehringer Ingelheim Pharmaceuticals Inc.
Bottino Anthony P.
Criares Theodore J.
Raymond Robert P.
Witkowski Timothy X.
LandOfFree
Methods of treating cytokine mediated diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating cytokine mediated diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating cytokine mediated diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3371100